

RPG LIFE SCIENCES LIMITED Unit No. 208-213, B Wing, Bezzola Complex, Sion-Trombay Road, Chembur, Mumbai 400071, India Tel: +91-22-25292152-55 Fax: +91-22-25297423

April 30, 2021

The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No. C-1, G- Block,
Bandra - Kurla Complex, Bandra (East)
Mumbai – 400 051

BSE Limited Corporate Relationship Department Floor 25, P.J. Towers, Dalal Street, Mumbai 400 001

Symbol: RPGLIFE Scrip Code: 532983

Dear Sirs,

Sub: Press Release - Financial Results

Please find enclosed herewith a copy of press release with respect to Audited Financial Results of the Company for the financial year ended March 31, 2021.

Kindly take the above on record.

Thanking you,

Yours Sincerely,
For RPG Life Sciences Limited

Rajesh Shirambekar

Head – Legal & Company Secretary

Encl.: as above

Philametar





Full Year Revenue up by 4% and PBT up by 47% over last year

Mumbai, 30 April, 2021: RPG Life Sciences Limited has announced its financial results for the quarter and year ended March 31, 2021.

	YoY Revenue from Operations	YoY PBT
Q4 FY 21 Highlights	Rs 92.76 crores – up from Rs 88.67 crores	Rs 8.95 crores – up from Rs 3.14 crores
Full year FY 21 Highlights	Rs 389.14 crores – up from Rs 375.57 crores	Rs 53.58 crores – up from Rs 36.45 crores

RPG Life Sciences, engaged in the manufacturing and marketing of pharmaceutical products, posted its Q4 and Full year results. For full year, revenue grew from Rs 375.57 crores to Rs 389.14 crores and PBT grew from Rs 36.45 crores to Rs 53.58 crores over last year. EBITDA margin also improved from 15.9% in FY 20 to 18.2% in FY 21, maintaining its upward trajectory. Q4 revenue was also up from Rs 88.67 crores to Rs 92.76 crores and PBT up from Rs 3.14 crores to Rs 8.95 crores versus last year.

Mr. Yugal Sikri, Managing Director, RPG Life Sciences Ltd. said, "In FY21, the overall performance of the Company continued to be strong, despite impact of extended Covid-19 pandemic. On full year basis, revenues and PBT grew by 4% and 47% respectively. EBITDA margin retained its upward trajectory growing from 15.9% to 18.2%. We continue to be focused on executing our turnaround strategy. It comprises of five initiatives viz. Product portfolio rejuvenation by building chronic and specialty portfolio with new launches; Building our strategic brand assets through life cycle management by introducing line extensions; Deepening our customer coverage in targeted therapies by expanding our field force and deploying digital; Augmenting sales force effectiveness by competencies building initiatives and Improving profitability by opex control, efficient manufacturing operations and sales hygiene."

RPG Life Sciences Ltd (<u>www.rpglifesciences.com</u>):

RPG Life Sciences Ltd, part of RPG Enterprises, is an integrated pharmaceutical company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. The company is a research-based pharmaceutical company, producing a wide range of quality, affordable medicines. Its brands are highly trusted by healthcare professionals and patients.

RPG Enterprises (<u>www.rpggroup.com</u>):

RPG Enterprises, established in 1979, is one of India's fastest growing business groups with a turnover of US\$ 4 Billion. The group has diverse business interests in the areas of Infrastructure, Tyres, Pharma, IT and Specialty as well as in emerging innovation-led technology businesses.

Media Contact:

Sumeet Chatterjee
Senior Vice President – Corporate Brand and Group Communications
+91 9820340650 | sumeet@rpg.in